antifungal/sarcoma

FIELD OF THE INVENTION This invention pertains to therapeutics for the treatment of synovial sarcoma. BACKGROUND OF THE INVENTION Human synovial sarcoma (SS) is a soft tissue sarcoma that is associated with a translocation event, t(X;18)(p11.2;q11.2), which fuses the SS18 gene on chromosome 18 to

FIELD OF THE INVENTION This invention pertains to therapeutics for the treatment of synovial sarcoma. BACKGROUND OF THE INVENTION Human synovial sarcoma (SS) is a soft tissue sarcoma that is associated with a translocation event, t(X; 18)(p11.2; q11.2), which fuses the SS18 gene on chromosome 18 to

TECHNICAL FIELD The present invention relates to a therapeutic agent for soft tissue sarcoma, which contains a histone deacetylase inhibitor as an active ingredient. BACKGROUND ART In general, when there is a report on a substance or a compound having an antitumor activity and the report is based

FIELD OF INVENTION This invention relates to the fields of genetic engineering and gene transfer. More specifically, the invention relates to recombinant retrovirus vectors derived from avian sarcoma leukosis viruses (ASLVs) having an expanded host range. In particular, this invention relates to

1. Field of the Invention The extracorporeal treatment of blood to remove immunoglobulins and circulating immune complexes may be useful in a variety of circumstances. For example, it is suspected that some cancer patients develop a particular immune complex consisting of the patient's own IgG and

The invention described herein was made in the course of work under a grant or award from the Department of Health, Education and Welfare. This invention relates to certain novel chemical compounds having antitumor activity against murine p 388 and L 1210 leukemias and Ridgway osteogenic sarcoma in

FIELD OF THE INVENTION The invention relates generally to the diagnosis and treatment of a cancer such as Ewing's sarcoma. In particular, it is related to the use of NKX2.2 expression or expression of downstream genes of NKX2.2 as diagnostic markers for Ewing's sarcoma. It is also related to

CLAIM OF PRIORITY This application is a national stage application under 35 U.S.C. .sctn. 371 of International Application No. PCT/US2013/064601, filed Oct. 11, 2013, published as International Publication No. WO 2014/062511 on Apr. 24, 2014, which claims priority from U.S. Ser. No. 61/714,179,

FIELD OF INVENTION This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a

This application claims the benefit of European Patent Application No. EP 03 028 144.8, filed Dec. 5, 2003. FIELD OF THE INVENTION The present invention relates to methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases,

FIELD OF THE INVENTION The present invention relates to methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to leukemia, human sarcomas and carcinomas. In accordance with the present

FIELD OF THE INVENTION The invention relates to compositions, methods and kits for treating a condition with a targeted hybrid polymerized liposomal nanoparticle as a novel drug delivery vehicle. The condition includes but is not limited to various cancers. The hybrid polymerized liposomal

2. REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 15, 2017, is named

2. REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 29, 2013, is named ENZ-109(CIP)_SL.txt and

2. REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 29, 2013, is named ENZ-109(CIP)_SL.txt and